Related Experiment Video
Updated: May 12, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
Epratuzumab for systemic lupus erythematosus
1Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. dwallace@ucla.edu
Lupus
|April 5, 2013
Abstract:
Epratuzumab (EMab, UCB, Immunomedics) is a humanized monoclonal antibody targeting CD22 that is being studied in clinical trials for patients with a variety of rheumatic and hematologic conditions, including systemic lupus erythematosus (SLE). An overview of its mechanism of action is followed by a summary of completed lupus studies, and a preview of studies in progress. The agent clearly has anti-inflammatory activity and is a potentially useful agent in the management of autoimmune disorders.